Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
The goal of this clinical research study is to study the safety of giving larger daily doses of proton radiation therapy than the standard dose levels given to treat lung cancer. Researchers want to find the highest daily dose of proton radiation that can be given without having to stop therapy due to side effects.
Checked against the public recordLast updated Jan 2, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Radiation: Proton Therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Histologically or cytologically documented NSCLC, SCLC, thymic tumors, or carcinoid tumors 2. Patients not receiving concurrent chemotherapy 3. Patients that are eligible for concurrent treatment with biologic agents (epidermal growth factor receptor \[EGFR\] or vascular endothelial growth factor \[VEGF\] inhibitors) will be eligible for the study. Exclusion Criteria: 1. Prior radiotherapy to the chest 2. Life expectancy \<6 months 3. Pregnancy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Texas MD Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 2, 2020. Always confirm current availability with the study team.